Skip to content

#政策/支付

Today 0 items
Oct 15Thu
  1. biopharmadive.com43

    CVS to pay $315M to settle opioid prescribing allegations

    CVS Pharmacy will pay the U.S. government $315 million to settle Justice Department allegations that it dispensed medically unnecessary opioid prescriptions and sought Medicare reimbursement for them, without admitting wrongdoing. The deal resolves a 2024 lawsuit and a whistleblower complaint by former employee Hilary Estright. CVS must set up a reporting hotline and monitor pharmacy dispensing patterns; it has previously paid $5 billion to settle opioid prescribing lawsuits.

Oct 14Wed
  1. statnews.com40

    STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine

    European Union antitrust regulators accepted concessions from Sanofi to settle a probe into a campaign that allegedly disparaged Fluad, the CSL Seqirus flu vaccine, as inferior to Sanofi's Efluelda vaccine in communications aimed at health care professionals in Germany and France, where Sanofi holds a dominant position. Sanofi avoided a fine by committing to a corrective communication campaign and refraining from such behavior in future, an agreement that is legally binding.

Oct 9Fri
  1. biospace.com58

    Merck barred from making subcutaneous Keytruda in 8 European countries

    A Dutch court has barred Merck from producing, importing, stocking or selling Keytruda SC, the subcutaneous formulation of Keytruda, in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, after finding it infringes a Halozyme Therapeutics patent covering MDASE technology. The decision follows a German preliminary injunction in December, and Merck's appeal of that ruling has a hearing expected next month. Subcutaneous Keytruda brought in $463 million of the franchise's $8.4 billion in second-quarter sales, and a key patent expires in 2028.

    Why it matters: Patent rulings now block subcutaneous Keytruda in key European markets, affecting Merck's strategy ahead of the 2028 patent expiry.

Aug 18Tue
  1. statnews.com40

    STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

    The Internal Revenue Service is investigating UnitedHealth, seeking to significantly increase taxable income for the years 2017 through 2020, and may require additional payments for years after 2020, according to a regulatory filing by the health insurer. STAT reports the probe in its Health Care Inc. newsletter alongside coverage of state laws that may be curbing private equity takeovers of physician groups.

Aug 17Mon
  1. statnews.com54

    STAT+: State laws may be curbing private equity takeovers of physician group

    Over a dozen US states have passed laws strengthening oversight of private equity deals in health care, and a new report says the rules are slowing dealmaking. Physician practice management deals are on track to fall by about half this year compared with 2025, and PitchBook data show investments in these firms, which handle clinics' billing and operations, dropped from 851 deals in 2021 to 105 in the first half of 2026.

Aug 15Sat
  1. STAT News61

    Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators

    The FTC, joined by attorneys general from multiple states, is examining Epic Systems Corp. for potential antitrust violations, contacting at least four people in recent months. Investigators are asking about employee noncompete-style agreements and alleged use of Epic's market position, covering records for 57% of US inpatient hospital beds, to block rivals from accessing patient data. The probe is early stage, may last years and may never lead to charges; Epic denies anticompetitive behavior.

    Why it matters: Federal and state antitrust scrutiny of the dominant US electronic health records vendor could affect data access and competition across health tech.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org